The mutational landscape of endometrial cancer

Current Opinion in Genetics and Development

Volumn 30, Issue , 2015, Pages 25-31

  Hong, Bo ^a   Le Gallo, Matthieu ^a   Bell, Daphne W ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A GENE; ARID1B GENE; CANCER INCIDENCE; CARCINOGENESIS; CDH19 GENE; CDKN1A GENE; CELP GENE; CHD4 GENE; COL11A1 GENE; COPY NUMBER VARIATION; CSMD3 GENE; ENDOMETRIUM CANCER; EP300 GENE; FAM132A GENE; FBXW7 GENE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HCFC1R1 GENE; HIST1H2AM GENE; HUMAN; MICROSATELLITE INSTABILITY; MUTATION RATE; MUTATIONAL ANALYSIS; PIK3CA GENE; PIK3R1 GENE; POLE GENE; PPP2R1A GENE; PRPF18 GENE; PTEN GENE; REVIEW; SLC9A11 GENE; SPOP GENE; TAF1 GENE; TP53 GENE; YIPF3 GENE; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOMICS; MUTATION; PATHOLOGY; UTERINE NEOPLASMS;

ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MUTATION; UTERINE NEOPLASMS;

EID: 84921450220     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2014.12.004     Document Type: Review

References (36)

1. American Cancer Society Cancer Facts & Figures 2014 2014, 1-67.
2. Dedes K.J., Wetterskog D., Ashworth A., Kaye S.B., Reis-Filho J.S. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011, 8:261-271.
3. Dowdy S.C. Improving oncologic outcomes for women with endometrial cancer: realigning our sights. Gynecol Oncol 2014, 133:370-374.
4. del Carmen M.G., Birrer M., Schorge J.O. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 2012, 127:651-661.
5. Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., Powell M.A., Hendrickson M.R., Kapp D.S., Chan J.K. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94:642-646.
6. O'Hara A.J., Bell D.W. The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012, 2012:33-47.
7. Kuhn E., Wu R.C., Guan B., Wu G., Zhang J., Wang Y., Song L., Yuan X., Wei L., Roden R.B., et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012, 104:1503-1513.
8. Le Gallo M., O'Hara A.J., Rudd M.L., Urick M.E., Hansen N.F., O'Neil N.J., Price J.C., Zhang S., England B.M., Godwin A.K., et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012, 44:1310-1315.
9. Zhao S., Choi M., Overton J.D., Bellone S., Roque D.M., Cocco E., Guzzo F., English D.P., Varughese J., Gasparrini S., et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A 2013, 110:2916-2921.
10. Liang H., Cheung L.W., Li J., Ju Z., Yu S., Stemke-Hale K., Dogruluk T., Lu Y., Liu X., Gu C., et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012, 22:2120-2129.
11. Kinde I., Bettegowda C., Wang Y., Wu J., Agrawal N., Shih Ie M., Kurman R., Dao F., Levine D.A., Giuntoli R., et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013, 5:167ra164.
12. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73. The Cancer Genome Atlas Research Network.
13. Ciriello G., Miller M.L., Aksoy B.A., Senbabaoglu Y., Schultz N., Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013, 45:1127-1133.
14. Kuhn E., Bahadirli-Talbott A., Shih Ie M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol 2014, 27:1014-1019.
15. Hayes M.P., Douglas W., Ellenson L.H. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009, 113:370-373.
16. Rudd M.L., Price J.C., Fogoros S., Godwin A.K., Sgroi D.C., Merino M.J., Bell D.W. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011, 17:1331-1340.
17. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
18. Burns M.B., Temiz N.A., Harris R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013, 45:977-983.
19. Kim T.M., Laird P.W., Park P.J. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013, 155:858-868.
20. Simpkins S.B., Bocker T., Swisher E.M., Mutch D.G., Gersell D.J., Kovatich A.J., Palazzo J.P., Fishel R., Goodfellow P.J. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999, 8:661-666.
21. Novetsky A.P., Zighelboim I., Thompson D.M., Powell M.A., Mutch D.G., Goodfellow P.J. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol 2013, 128:470-474.
22. Zighelboim I., Mutch D.G., Knapp A., Ding L., Xie M., Cohn D.E., Goodfellow P.J. High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers. Hum Mutat 2014, 35:63-65.
23. Anastas J.N., Moon R.T. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013, 13:11-26.
24. Helming K.C., Wang X., Wilson B.G., Vazquez F., Haswell J.R., Manchester H.E., Kim Y., Kryukov G.V., Ghandi M., Aguirre A.J., et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014, 20:251-254.
25. The Cancer Genome Atlas Research Network, Weinstein J.N., Collisson E.A., Mills G.B., Shaw K.R., Ozenberger B.A., Ellrott K., Shmulevich I., Sander C., Stuart J.M. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013, 45:1113-1120.
26. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
27. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
28. Gonzalez-Perez A., Perez-Llamas C., Deu-Pons J., Tamborero D., Schroeder M.P., Jene-Sanz A., Santos A., Lopez-Bigas N. IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods 2013, 10:1081-1082.
29. Tamborero D., Gonzalez-Perez A., Perez-Llamas C., Deu-Pons J., Kandoth C., Reimand J., Lawrence M.S., Getz G., Bader G.D., Ding L., et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 2013, 3:2650.
30. Zack T.I., Schumacher S.E., Carter S.L., Cherniack A.D., Saksena G., Tabak B., Lawrence M.S., Zhang C.Z., Wala J., Mermel C.H., et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013, 45:1134-1140.
31. Tafe L.J., Riggs E.R., Tsongalis G.J. Lynch syndrome presenting as endometrial cancer. Clin Chem 2014, 60:111-121.
32. Tan M.H., Mester J.L., Ngeow J., Rybicki L.A., Orloff M.S., Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012, 18:400-407.
33. Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 2014, 32:1818-1824.
34. Daniels M.S. Genetic testing by cancer site: uterus. Cancer J 2012, 18:338-342.
35. Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., Kemp Z., Spain S.L., Almeida E.G., Salguero I., et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013, 45:136-144.
36. Rohlin A., Zagoras T., Nilsson S., Lundstam U., Wahlstrom J., Hulten L., Martinsson T., Karlsson G.B., Nordling M. A mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol 2014, 45:77-81.